U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Abnormal peripheral myelination

MedGen UID:
871174
Concept ID:
C4025648
Anatomical Abnormality
HPO: HP:0003130

Definition

An abnormality of the myelination of motor and sensory peripheral nerves. These are axons for motor nerves and dendrites for sensory nerves in the strict anatomic sense. [from HPO]

Conditions with this feature

Cockayne syndrome type 2
MedGen UID:
155487
Concept ID:
C0751038
Disease or Syndrome
Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the "classic" or "moderate" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).
Cockayne syndrome type 1
MedGen UID:
155488
Concept ID:
C0751039
Disease or Syndrome
Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the "classic" or "moderate" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).

Professional guidelines

PubMed

Jerath NU, Shy ME
Biochim Biophys Acta 2015 Apr;1852(4):667-78. Epub 2014 Aug 6 doi: 10.1016/j.bbadis.2014.07.031. PMID: 25108281
Pareyson D, Marchesi C
Adv Exp Med Biol 2009;652:207-24. doi: 10.1007/978-90-481-2813-6_14. PMID: 20225028
Jani-Acsadi A, Krajewski K, Shy ME
Semin Neurol 2008 Apr;28(2):185-94. doi: 10.1055/s-2008-1062264. PMID: 18351520

Recent clinical studies

Etiology

Biffi A, Aubourg P, Cartier N
Hum Mol Genet 2011 Apr 15;20(R1):R42-53. Epub 2011 Mar 31 doi: 10.1093/hmg/ddr142. PMID: 21459776
Vital A
Brain Pathol 2001 Oct;11(4):399-407. doi: 10.1111/j.1750-3639.2001.tb00407.x. PMID: 11556684Free PMC Article
Keller MP, Chance PF
Semin Neurol 1999;19(4):353-62. doi: 10.1055/s-2008-1040850. PMID: 10716658
Chance PF, Reilly M
Curr Opin Neurol 1994 Oct;7(5):372-80. doi: 10.1097/00019052-199410000-00002. PMID: 7804455
Chance PF, Pleasure D
Arch Neurol 1993 Nov;50(11):1180-4. doi: 10.1001/archneur.1993.00540110060006. PMID: 8215977

Diagnosis

Traub R, Qarni T, Cohen AD, Karam C
Muscle Nerve 2024 Aug;70(2):173-179. Epub 2024 May 30 doi: 10.1002/mus.28164. PMID: 38816958
Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, Luo Z, Hu J, Peng S
Front Endocrinol (Lausanne) 2023;14:1265372. Epub 2024 Jan 9 doi: 10.3389/fendo.2023.1265372. PMID: 38264279Free PMC Article
Koike H, Katsuno M
Neurol Sci 2021 Nov;42(11):4489-4501. Epub 2021 Sep 16 doi: 10.1007/s10072-021-05583-7. PMID: 34529193
Attarian S, Fatehi F, Rajabally YA, Pareyson D
J Neurol 2020 Aug;267(8):2198-2206. Epub 2019 Apr 15 doi: 10.1007/s00415-019-09319-8. PMID: 30989370
Allen JA, Parry GJ
Semin Neurol 2015 Aug;35(4):398-406. Epub 2015 Oct 6 doi: 10.1055/s-0035-1558974. PMID: 26502763

Therapy

Latov N, Brannagan TH 3rd, Sander HW, Gondim FAA
Arq Neuropsiquiatr 2024 Jun;82(6):1-7. Epub 2024 Feb 7 doi: 10.1055/s-0043-1777728. PMID: 38325389Free PMC Article
Stavrou M, Sargiannidou I, Georgiou E, Kagiava A, Kleopa KA
Int J Mol Sci 2021 Jun 3;22(11) doi: 10.3390/ijms22116048. PMID: 34205075Free PMC Article
Weaver LK
Undersea Hyperb Med 2020 First Quarter;47(1):151-169. doi: 10.22462/01.03.2020.17. PMID: 32176957
Niimi N, Takaku S, Yako H, Sango K
Adv Exp Med Biol 2019;1190:357-369. doi: 10.1007/978-981-32-9636-7_23. PMID: 31760656
Evans OB, Vedanarayanan V
Pediatr Rev 1997 Jan;18(1):10-6. doi: 10.1542/pir.18-1-10. PMID: 8993064

Prognosis

Latov N, Brannagan TH 3rd, Sander HW, Gondim FAA
Arq Neuropsiquiatr 2024 Jun;82(6):1-7. Epub 2024 Feb 7 doi: 10.1055/s-0043-1777728. PMID: 38325389Free PMC Article
Allen JA, Parry GJ
Semin Neurol 2015 Aug;35(4):398-406. Epub 2015 Oct 6 doi: 10.1055/s-0035-1558974. PMID: 26502763
Rosen BA
Pediatr Rev 2012 Apr;33(4):164-70; quiz 170-1. doi: 10.1542/pir.33-4-164. PMID: 22474113
Evans OB, Vedanarayanan V
Pediatr Rev 1997 Jan;18(1):10-6. doi: 10.1542/pir.18-1-10. PMID: 8993064
Chance PF, Reilly M
Curr Opin Neurol 1994 Oct;7(5):372-80. doi: 10.1097/00019052-199410000-00002. PMID: 7804455

Clinical prediction guides

Latov N, Brannagan TH 3rd, Sander HW, Gondim FAA
Arq Neuropsiquiatr 2024 Jun;82(6):1-7. Epub 2024 Feb 7 doi: 10.1055/s-0043-1777728. PMID: 38325389Free PMC Article
Van Lent J, Vendredy L, Adriaenssens E, Da Silva Authier T, Asselbergh B, Kaji M, Weckhuysen S, Van Den Bosch L, Baets J, Timmerman V
Brain 2023 Jul 3;146(7):2885-2896. doi: 10.1093/brain/awac475. PMID: 36511878Free PMC Article
Hou X, Liang Y, Cui P, Hao J
Mult Scler 2022 Mar;28(3):453-462. Epub 2021 Oct 1 doi: 10.1177/13524585211028126. PMID: 34595962
Weaver LK
Undersea Hyperb Med 2020 First Quarter;47(1):151-169. doi: 10.22462/01.03.2020.17. PMID: 32176957
Allen JA, Parry GJ
Semin Neurol 2015 Aug;35(4):398-406. Epub 2015 Oct 6 doi: 10.1055/s-0035-1558974. PMID: 26502763

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...